Komori
Governance4502Takeda Pharmaceutical Company LimitedPharmaceuticals

Report on Corporate Governance 2026/07/09

From fiscal 2026, the linkage to divisional performance will be discontinued for part of the bonuses paid to in-house directors other than the CEO, and changed to linkage to individual performance.

Worth reading
70In focus
Scored from 2 of 5 sections
Direction
Neutral
Direction inferred from the company’s description.
Scale
25
Percentage of bonus (%)
Wording
Definitive
How definitive the wording is.

Governance structure

Company with an Audit and Supervisory Committee
Committee3
Advisory CommitteeNomination Committeeand Compensation Committee. All members of the Compensation Committee are outside directors. The proportion of outside members on the Nomination Committee is not disclosed.
Changes this time

From fiscal 2026, for 25% of the bonuses paid to in-house directors other than the CEO, the linkage to the achievement level of divisional performance indicators will be discontinued and changed to linkage to individual performance.

Governance structure
ItemDetails
Corporate Governance StructureCompany with an Audit and Supervisory Committee
CommitteeAdvisory Committee, Nomination Committee, and Compensation Committee. All members of the Compensation Committee are outside directors. The proportion of outside members on the Nomination Committee is not disclosed.
Changes this timeFrom fiscal 2026, for 25% of the bonuses paid to in-house directors other than the CEO, the linkage to the achievement level of divisional performance indicators will be discontinued and changed to linkage to individual performance.
Items this document does not state (5)
Number of directorsNumber of independent officersPolicy on cross-shareholdingsTakeover defensesControlling shareholder

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

Not stated.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
Report on Corporate Governance 2026/07/09 | Takeda Pharmaceutical Company Limited (4502) timely disclosure | Komori